Poor Response to Substitution Therapy with Cortisone Acetate in Patients with Congenital Adrenal Hyperplasia

Although cortisone acetate is approved worldwide as corticosteroid substitution therapy in congenital adrenal hyperplasia (21-hydroxylase deficiency), its effectiveness is uncertain since its biologic activity depends on activation by 11β-hydroxysteroid dehydrogenase (11β-HSD). We sought to compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Inada, Hiroshi, Imamura, Takuji, Nakajima, Ryoichi, Yamano, Tsunekazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society for Pediatric Endocrinology 2004
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004908/
https://www.ncbi.nlm.nih.gov/pubmed/24790292
http://dx.doi.org/10.1297/cpe.13.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004908/
https://www.ncbi.nlm.nih.gov/pubmed/24790292
http://dx.doi.org/10.1297/cpe.13.11

Ejemplares similares